Senhwa Biosciences, Inc. (TPEX:6492)
Taiwan · Delayed Price · Currency is TWD 54.10
-1.40 (-2.52%)
At close: Mar 24, 2026
Senhwa Biosciences Revenue
In the year 2025, Senhwa Biosciences had annual revenue of 1.07M TWD with 7.00% growth. Senhwa Biosciences had revenue of 240.00K in the quarter ending December 31, 2025, a decrease of -4.00%.
Revenue
1.07M
Revenue Growth
+7.00%
P/S Ratio
4,519.42
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.07M | 70.00K | 7.00% |
| Dec 31, 2024 | 1.00M | - | - |
| Dec 31, 2023 | 1.00M | - | - |
| Dec 31, 2022 | 1.00M | 450.00K | 81.82% |
| Dec 31, 2021 | 550.00K | -67.00K | -10.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.37B |
| Panion & Bf Biotech | 2.06B |
| Medigen Biotechnology | 1.58B |
| BioGend Therapeutics | 222.34M |
| Pharmosa Biopharm | 67.27M |
| OBI Pharma | 58.58M |
| UnicoCell Biomed | 30.10M |
| AnnJi Pharmaceutical | 23.85M |
Senhwa Biosciences News
- 6 months ago - Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Benzinga